These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7532595)

  • 1. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
    Fan N; Evans DB; Rank KB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Feb; 359(2-3):233-8. PubMed ID: 7532595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
    Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s.
    Fan N; Rank KB; Evans DB; Thomas RC; Tarpley WG; Sharma SK
    FEBS Lett; 1995 Aug; 370(1-2):59-62. PubMed ID: 7544302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
    Kleim JP; Bender R; Kirsch R; Meichsner C; Paessens A; Riess G
    Virology; 1994 May; 200(2):696-701. PubMed ID: 7513921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors.
    Goldman ME; O'Brien JA; Ruffing TL; Schleif WA; Sardana VV; Byrnes VW; Condra JH; Hoffman JM; Emini EA
    Antimicrob Agents Chemother; 1993 May; 37(5):947-9. PubMed ID: 7685996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.
    Nunberg JH; Schleif WA; Boots EJ; O'Brien JA; Quintero JC; Hoffman JM; Emini EA; Goldman ME
    J Virol; 1991 Sep; 65(9):4887-92. PubMed ID: 1714522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.
    Sardana VV; Emini EA; Gotlib L; Graham DJ; Lineberger DW; Long WJ; Schlabach AJ; Wolfgang JA; Condra JH
    J Biol Chem; 1992 Sep; 267(25):17526-30. PubMed ID: 1381350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
    Balzarini J; Karlsson A; Meichsner C; Paessens A; Riess G; De Clercq E; Kleim JP
    J Virol; 1994 Dec; 68(12):7986-92. PubMed ID: 7525984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
    Esnouf RM; Ren J; Hopkins AL; Ross CK; Jones EY; Stammers DK; Stuart DI
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3984-9. PubMed ID: 9108091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
    Dueweke TJ; Poppe SM; Romero DL; Swaney SM; So AG; Downey KM; Althaus IW; Reusser F; Busso M; Resnick L
    Antimicrob Agents Chemother; 1993 May; 37(5):1127-31. PubMed ID: 7685995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
    Romero DL; Olmsted RA; Poel TJ; Morge RA; Biles C; Keiser BJ; Kopta LA; Friis JM; Hosley JD; Stefanski KJ; Wishka DG; Evans DB; Morris J; Stehle RG; Sharma SK; Yagi Y; Voorman RL; Adams WJ; Tarpley WG; Thomas RC
    J Med Chem; 1996 Sep; 39(19):3769-89. PubMed ID: 8809165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
    Olmsted RA; Slade DE; Kopta LA; Poppe SM; Poel TJ; Newport SW; Rank KB; Biles C; Morge RA; Dueweke TJ; Yagi Y; Romero DL; Thomas RC; Sharma SK; Tarpley WG
    J Virol; 1996 Jun; 70(6):3698-705. PubMed ID: 8648704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Emini EA; Byrnes VW; Condra JH; Schleif WA; Sardana VV
    Arch Virol Suppl; 1994; 9():11-7. PubMed ID: 7518271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
    Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.
    Byrnes VW; Sardana VV; Schleif WA; Condra JH; Waterbury JA; Wolfgang JA; Long WJ; Schneider CL; Schlabach AJ; Wolanski BS
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1576-9. PubMed ID: 7692811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.
    Vasudevachari MB; Battista C; Lane HC; Psallidopoulos MC; Zhao B; Cook J; Palmer JR; Romero DL; Tarpley WG; Salzman NP
    Virology; 1992 Sep; 190(1):269-77. PubMed ID: 1382341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
    Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
    Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
    Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
    J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.